Literature DB >> 24639563

More effective agents still needed for progressive radioiodine-refractory differentiated thyroid cancer.

Chen-Tian Shen, Zhong-Ling Qiu, Quan-Yong Luo.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24639563     DOI: 10.1530/ERC-14-0094

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


× No keyword cloud information.
  1 in total

1.  Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.

Authors:  Marco Gallo; Federica Michelon; Anna Castiglione; Francesco Felicetti; Alessandro Adriano Viansone; Alice Nervo; Clizia Zichi; Giovannino Ciccone; Alessandro Piovesan; Emanuela Arvat
Journal:  Endocrine       Date:  2014-11-21       Impact factor: 3.633

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.